Crinetics Pharmaceuticals, Inc.
CRNX
Helyezés a részvények között
#2228
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Részvényárfolyam
$84.95
Utolsó szinkronizálás: 2026-09-01
Piaci kapitalizáció
$9.00B
Változás (1 nap)
0.00%
Változás (1 év)
98.25%
Ország
US
Kereskedés Crinetics Pharmaceuticals, Inc. (CRNX)
Kategória
Healthcare
Crinetics Pharmaceuticals, Inc. (CRNX) P/B aránya
P/B arány ekkor: October 2026 TTM: 7.52
Crinetics Pharmaceuticals, Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi könyv szerinti árfolyam aránya (P/B, TTM) 7.52. 2023 végén ez az arány 3.83 volt.
P/B arány története a(z) Crinetics Pharmaceuticals, Inc. esetén 2016 és 2026 között
P/B arány az év végén
| Év | P/B arány | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 7.52 | 141.13% |
| 2024 | 3.12 | -18.65% |
| 2023 | 3.83 | 27.45% |
| 2022 | 3.01 | -8.58% |
| 2021 | 3.29 | 29.34% |
| 2020 | 2.54 | -139.33% |
| 2019 | -6.47 | -22.97% |
| 2018 | -8.39 | -62.93% |
| 2017 | -22.64 | -58.70% |
| 2016 | -54.83 | 0.00% |
P/B arány hasonló vállalatoknál vagy versenytársaknál
| Vállalat | P/B arány | P/B arány különbség | Ország |
|---|---|---|---|
| 6.251 | -16.91% |
US
|
|
| 13.2547 | 76.18% |
US
|
|
| 4.208 | -44.07% |
AU
|
|
| 6.1824 | -17.82% |
NL
|
|
| - | - |
CH
|
